Clinical Trial Update: Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BAY59-8862 in taxane-resistant metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BAY59-8862 (BAY59-8862)

Snippet

Sponsor: Bayer | Conditions: Breast Neoplasms, Breast Cancer, Metastatic | Phase 2 | Status: COMPLETED